ficance for the promotion of postoperative rehabilitation, which is worthy of popularization in clinical practice.Purpose This study was undertaken to investigate the anticancer effects of Sulforaphane against liver cancer and to elucidate the underlying molecular mechanisms. Methods WST-1 assay was used to monitor the proliferation rate. DAPI and annexin V/propidium iodide (PI) staining was used for apoptosis. Flow cytometry was used for cell cycle analysis. Wound heal and transwell assays were used to monitor cell migration and invasion. The protein expression was determined by western blot analysis. Results It was found that Sulforaphane decreased the viability of the liver cancer HepG2 cells and exhibited an IC50 of 9 µM. Nonetheless, Sulforaphane (µM) exerted very low toxic effects on the normal AML12 hepatocytes and exhibited an IC50 of 100 µM. Flow cytometery analysis showed that Sulforaphane triggered G2/M arrest of the liver HepG2 cancer cells. DAPI staining revealed that Sulforaphane triggered the apoptotic cell death of HepG2 cells which was accompanied with activation of caspases 3 and 9, upregulation of Bax and downregulation of Bcl-2. Transwell assays showed that Sulforaphane inhibited the migration and invasion of the HepG2 liver cancer cells in a dose dependent manner. The effects of Sulforaphane were also investigated on the MAPK7 signalling pathway and it was found that Sulforaphane could block this pathway in HepG2 cells. Conclusion Taken together, Sulforaphane may prove essential in the development of chemotherapy for liver cancers.Purpose To investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with iodine-125 (125I) seed implantation and three-dimensional conformal radiotherapy (3DCRT) in treating primary hepatocellular carcinoma (HCC) in the advanced stage. Methods A total of 110 primary HCC patients in the advanced stage without operative indications admitted to and treated in our hospital from March 2014 to March 2016 were selected and divided into two groups using randomized single-blind method to receive TACE and 125I seed implantation combined with 3DCRT (TACE + 125I + 3DCRT group, n=55) as well as TACE combined with 3DCRT (TACE + 3DCRT group, n=55) separately. The short-term clinical efficacy, changes in the levels of alpha fetoprotein (AFP), insulin-like growth factor-II (IGF-II) and insulin-like growth factor binding protein-2 (IGFBP-2) in the serum before and after treatment, adverse reactions and long-term survival of the patients were observed and recorded. Results TACE + 125I + 3DCRT group had significantly higher objective response rate (ORR) and disease control rate (DCR) than TACE + 3DCRT group [83.6% (46/55) vs. 63.6% (35/55), 96.4% (53/55) vs. 83.6% (46/55)] (p=0.029, p=0.043). The levels of serum AFP, IGF-II and IGFBP-2 declined markedly after treatment in both groups compared with those before treatment (p0.05). The results of follow-up indicated that TACE + 125I + 3DCRT group had notably longer overall survival (OS) and progression-free survival (PFS) than TACE + 3DCRT group (p=0.030, p=0.016). Conclusion The treatment scheme of TACE and 125I seed implantation combined with 3DCRT have exact efficacy in advanced primary HCC, which can distinctly increase the ORR and DCR, prominently reduce the levels of serum AFP, IGF-II and IGFBP-2 and prolong the survival time of the patients without increasing adverse reactions compared with TACE + 3DCRT, so it is worthy of clinical popularization and application.Purpose To explore the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma. Methods 118 patients with advanced hepatocellular carcinoma treated in our hospital from June 2014 to June 2016 were collected and randomly divided into the Sorafenib+TACE group (treated with Sorafenib combined with TACE, n=59) and the TACE group (n=59). The clinical efficacy, the changes in levels of serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and alpha fetoprotein (AFP) before and after treatment, adverse reactions and postoperative survival of patients were observed and recorded. Results The objective response rate (ORR) and the disease control rate (DCR) were 55.9% (33/59) and 86.4% (51/59) in the Sorafenib+TACE group, and 37.3% (22/59) and 67.8% (40/59) in the TACE group. Both ORR and DCR in the Sorafenib+TACE group were significantly superior to those in the TACE group (p=0.022, p=0.027). Main adversiously reduce the levels of serum VEGF, bFGF and AFP, and prolong the survival of patients with advanced hepatocellular carcinoma, while the adverse reactions are tolerable, so it is worthy of clinical popularization and application.Purpose Whether primary tumor resection (PTR) should be performed in patients with asymptomatic colorectal cancer (CRC) and unresectable synchronous metastasis is controversial. The purpose of this study was to investigate the prognostic impact of initial primary tumor resection in patients with synchronous unresectable metastatic CRC. Methods The patients with unresectable synchronous metastatic CRC who had undergone primary tumor resection and then received chemotherapy were compared with the patients who received only palliative systemic chemotherapy. Results Survival analysis showed that median overall survival (OS) for all patients was 22.37 months. Primary tumor resection was associated with a significant survival benefit on unadjusted analysis (median survival 29.56 months vs. 14.25 months; p less then 0.001). Two-year, 3-year and 5-year survival rates were 57%, 35%, 19% for the PTR group and 30%, 16%, 8% for the non-PTR group and all results were statistically significant and favored surgery. https://www.selleckchem.com/products/az-33.html Conclusions Our study suggests that primary tumor resection improves the survival of patients with metastatic CRC and unresectable synchronous metastasis.Purpose Anastomotic leakage (AL) is one of the most serious complications of colorectal surgery. We investigated whether the large-calibre transanal drainage tube (LTDT) placement could reduce AL after anterior resection for rectal cancer. Methods We restrospectively analyzed 222 patients who underwent anterior resection at our institution. The patients were divided into the large-calibre transanal drainage tube (LTDT) and non-transanal drainage tube (NTDT) groups according to whether the large-calibre transanal drainage tube was placed in the operation. Clinical characteristics and postoperative complication were compared between the LTDT and NTDT groups. Results In the LTDT group, AL occurred in 0 patient, whereas it occurred in 9 patients in the NTDT group. The rate of AL was significantly lower in the LTDT group (0 vs. 6.6%; p=0.015). Eight cases of AL were treated conservatively. One case developed severe peritonitis and underwent re-operation receiving temporary stoma.No perioperative death occurred in this series.